Nordic Nanovector
Dr. Jostein Dahle has more than 20 years of experience in cancer research. He is one of the inventors of Betalutin® and the founders of Nordic Nanovector. Dr. Dahle has previously held the position of chief executive officer of Nordic Nanovector and leader of the radioimmunotherapy group at the Institute for Cancer Research at the Norwegian Radium Hospital. He has published more than 50 papers in the field of cancer and biotechnology. Dr. Dahle holds an MSc in biophysics from the Norwegian University for Science and Technology in Trondheim (1995) and a Ph.D. in radiation biology from the University of Oslo (2000) and received post-doctoral training in UV-carcinogenesis in the department of radiation biology (2001-2004), the Norwegian Radium Hospital. Dr. Dahle has been with the company since its incorporation in 2008.
This person is not in any offices
Nordic Nanovector
Nordic Nanovector is committed to developing and delivering innovative therapies to patients to address major unmet medical needs. The Company aspires to become a leader in the development of CD37-targeted therapies for hematological cancers and immune diseases.